Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2261-2268

  Celio, Luigi ^a   Martinetti, Antonia ^a   Ferrari, Leonardo ^a   Buzzoni, Roberto ^a   Mariani, Luigi ^a   Miceli, Rosalba ^a   Seregni, Ettore ^a   Procopio, Giuseppe ^a   Cassata, Antonio ^a   Bombardieri, Emilio ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Aromatase inhibition; Formestane; GnRH analog; Premenopausal breast cancer

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; FORMESTANE; GONADORELIN DERIVATIVE; GONADOTROPIN; SEX HORMONE BINDING GLOBULIN; TRIPTORELIN;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; GONADOTROPIN BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR REGRESSION;

ADULT; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; TRIPTORELIN;

EID: 0032805333     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Santen RJ, Manni A, Harvey H: Gonadotropin releasing hormone (GnRH) analogs for the treatment of breast cancer and prostatic carcinoma. Breast Cancer Res Treat 7: 129-145, 1986.
2. Grodin JM, Siiteri PK, McDonald PC: Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36: 207-214, 1973.
3. Miller WR: Aromatase inhibitors and breast cancer. Cancer Treat Rev 23: 171-187, 1997.
4. Santen RJ, Samojlik E, Wells SA: Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51: 473-477, 1980.
5. Harris AL, Dowsett M, Jeffcoate SL, McKinna JA, Morgan M, Smith IE: Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 55: 718-722, 1982.
6. Wander HE, Blossey HC, Nagel GA: Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22: 1371-1374, 1986.
7. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Molec Biol 43: 155-159, 1992.
8. Coombes RC, Stein RC, Dowsett M: Aromatase inhibitors in human breast cancer. Proc Roy Soc Edin , 95 B: 283-291, 1989.
9. Neskovic-Konstanlinovic ZB, Vuletic LB, Nikolic-Stanojevic LI, et al: Therapeutic and endocrine effects of Decapeptyl, synthetic LH-RH agonistic analog in premenopausal women with metastatic breast cancer. Oncology 51: 95-101, 1994.
10. Bajetta E, Zilembo N, Barni S, et al: A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. Ann Oncol 8: 649-654, 1997.
11. Paradisi R, Lodi S, Bolelli G, Venturoli S: Radioimmunoassay of three oestrogens and three androgens in the same plasma sample after extraction and chromatographic separation. Acta Endocrinol 94: 229-234, 1980.
12. Ciotti PM, Franceschetti F, Bulletti C, Jasonni VM, Bolelli GF: Rapid and specific RIA of serum estrone sulfate with selective solid phase extraction. J Steroid Biochem 32: 473-474, 1989.
13. Bajetta E, Zilembo N, Buzzoni R, et al: Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 51: 262-269, 1994.
14. Searle SR, Casella G, McCulloch CE: Variance components. (John Wiley and Sons, eds) New York, 1992
15. SAS Institute Inc. SAS technical report P-229 - SAS/STAT: Software: changes and enhancements. Cary, NC, USA 1992
16. Vermeulen A: The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 42: 247-253, 1976.
17. Pasqualini JR, Chetrite G, Blacker C, et al: Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81: 1460-1464, 1996.
18. Nicholson RI, Walker KJ, Walker RF, et al: Review of the endocrine actions of luteinising hormone-releasing hormone analogs in premenopausal women with breast cancer. Horm Res 32 (suppl 1): 198-201, 1989.
19. Ferrari V, Zaniboni A, Simoncini E, et al: Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlation. Chemioterapia 7: 414-419, 1988.
20. Klijn JGM, De Jong FH: Long term treatment with the LH-RH agonist buserelin (Hoe 766) for metastatic breast cancer in single and combined drug regimens. In: LH-RH and its analogues (Labrie F, Belanger A, Dupont A, eds) Dordrecht: Elsevier, 1984, pp 425-437.
21. Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ: The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 28A: 1712-1716, 1992.
22. Lonning PE: Pharmacology of new aromatase inhibitors. Breast 5: 202-208, 1996.
23. Santner SJ, Feil PD, Santen RJ: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59: 29-33, 1984.
24. Dowsett M, Cantwell B, Anshumala L, Jeffcoate SL, Harris AL: Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 66: 672-677, 1988.
25. Dowsett M, Cunningham DC, Stein RC, et al: Dose-related endocrine effects and pharmacokinetics of oral and Intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49: 1306-1312, 1989.
26. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J: Regulation of aromatase activity within the breast. J Steroid Biochem Molec Biol 61: 193-202, 1997.
27. Reed MJ, Lai LC, Owen AM, et al: Effect of treatment with 4-hydroxyandrostenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res 50: 193-196, 1990.
28. Simpson ER, Mahendroo MS, Means GD, et al: Aromatase cytochrome p450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15: 342-355, 1994.
29. Walker KJ, Turkes A, Williams MR, Blarney RW, Nicholson RI: Preliminary endocrinological evaluation of a sustained-released formulation of the LH-releasing hormone agonist D-Ser(Bu)6Azgly 10LHRH in premenopausal women with advanced breast cancer. J Endocr 111: 349-353, 1986.
30. Ying S-Y: Inhibins, activins and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev 9: 267-293, 1988.
31. Hayes FJ, Hall JE, Boepple PA, Crowley WF: Differential control of gonadotropin secretion in the human: endocrine role of inhibin. J Clin Endocrinol Metab 83: 1835-1841, 1998.
32. Howell R, Dowsett M, King N, Edmonds DK: Endocrine effects of GnRH analogue with low-dose hormone replacement therapy in women with endometriosis. Clin Endocrinol 43: 609-615, 1995.
33. Anderson DC: Sex hormone-binding globulin: Clin Endocrinol 3: 69-96, 1974.
34. Santen RJ: Estrogen synthesis inhibitors: from "off the rack" to haute couture. J Clin Endocrinol Metab 77: 316-318, 1993.